I-MAK Defends ‘Patent Thicket’ Claims In Response To Thom Tillis Letter

The Organization Was Accused By The Senator Of Peddling Inaccuracies

16 Mar 2022

The Initiative for Medicines, Access & Knowledge has responded to criticisms leveled by North Carolina senator Thom Tillis at a report it published in 2018. The report accuses pharmaceutical firms of using patent thickets to suppress generic and biosimilar competition in the US market.

(Patent) Thicket, Trees In A Forest — I-MAK has defended its claims that patent thickets block generic and biosimilar market entry • Source: Mateusz Kubacki / Alamy Stock Photo

I-MAK Defends ‘Patent Thicket’ Claims In Response To Thom Tillis Letter

The Organization Was Accused By The Senator Of Peddling Inaccuracies

More from Legal & IP

More from Generics Bulletin